Home›Trial›NCT06872125

🔬NCT06872125Phase 3RECRUITING

A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

Study Summary

The purpose of the study is to evaluate the efficacy, safety, and tolerability of zorevunersen in Patients with Dravet syndrome.

Conditions

Dravet Syndrome

Interventions / Drugs

zorevunersen Sham Comparator

View on ClinicalTrials.gov ↗

Sponsor

Stoke Therapeutics

Study Details

Enrollment170 participants

Primary Completion—

Lead SponsorStoke Therapeutics, Inc

Data Retrieved2026-04-11 04:28:23.454410+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.